HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) by Boers, James E et al.
HER2 status in gastro-oesophageal adenocarcinomas assessed
by two rabbit monoclonal antibodies (SP3 and 4B5) and two
in situ hybridization methods (FISH and SISH)
James E. Boers, Harrie ¨tte Meeuwissen & Natalie Methorst
Pathology, Isala klinieken, Zwolle, the Netherlands
Date of submission 1 December 2009
Accepted for publication 20 April 2010
Boers J E, Meeuwissen H & Methorst N
(2011) Histopathology 58, 383–394
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal
antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)
Aims: HER2 gene ampliﬁcation has been detected in
10–20% of gastric adenocarcinomas. In view of the
recently demonstrated clinical beneﬁt of the anti-
human epidermal growth factor receptor 2 (HER2)
drug trastuzumab in the treatment of advanced gastric
cancer, reliable HER2 testing is of key importance. The
aim of this study was to examine HER2 status in
gastro-oesophageal adenocarcinomas comparing SP3
and 4B5 immunohistochemistry (IHC) with dual probe
HER2 [ﬂuorescence in situ hybridization (FISH) and
silver in situ hybridization (SISH)].
Methods and results: IHC and SISH were carried out on
biopsyspecimensof146patientswithadenocarcinomas
of the oesophagus and stomach. All SP3-IHC-positive
casesand91%of4B5-IHC-positivecaseswereampliﬁed.
Sensitivity of SP3-IHC-positivity and 4B5-IHC-positivity
forampliﬁcationwas77%and96%,respectively.Results
of FISH performed in 42 cases were identical to SISH.
Ampliﬁcation was heterogeneous in 73% of the adeno-
carcinomas; 24% of the oesophago-gastric carcinomas
and 7% of distal stomach tumours were ampliﬁed.
Conclusions: HER2-positivity is present in a signiﬁcant
proportion of oesophago-gastric adenocarcinomas
(24%), but at a lower rate in the distal stomach (7%).
Sensitivity for ampliﬁcation is higher with 4B5 IHC
than with SP3. FISH and SISH yield identical results,
but assessment is much easier with SISH. Our ﬁndings
provide important guidance for HER2-testing in gastro-
oesophageal adenocarcinomas for patients in whom
anti-HER2 treatment is considered.
Keywords: Anti-HER2 therapy, gastric adenocarcinoma, HER2, immunohistochemistry, in situ hybridization,
oesophageal adenocarcinoma
Abbreviations: ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; Chr17,
chromosome 17; CISH, chromogen in situ hybridization; DAB, 3,3¢ dia minobenzidine; EGJ, oesophago-gastric
junction; EGR, oesophago-gastric region; FDA, Federal Drug Agency; FISH, ﬂuorescence in situ hybridization; H&E,
haematoxylin and eosin; HER1, human epidermal growth factor receptor 1; HER2, human epidermal growth factor
receptor 2; H-score, histoscore; IHC, immunohistochemistry; ISH, in situ hybridization; NA, numerical aperture;
NPV, negative predictive value; PPV, positive predictive value; RT, room temperature; SISH, silver in situ
hybridization; TMA, tissue microarray
Introduction
Therapies directed against tumours overexpressing the
transmembranous human epidermal growth factor
receptor 2 (HER2) as a result of HER2-ampliﬁcation
has become widely available in the last decade for
breast carcinomas. HER2-positivity is reported in other
carcinomas, most notably gastric and oesophageal
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1–19 A large phase III trial employing
trastuzumab, directed against the HER2 protein, has
been conducted for advanced gastric carcinomas
showing clinical beneﬁt (ToGA trial
20).
Adenocarcinomas of the distal oesophagus, oeso-
phago–gastric junction (EGJ) and gastric cardia carci-
nomas share many risk factors, and the incidence of
these tumours has risen dramatically in the developed
world.
21,22 On the other hand, gastric carcinomas
situated in the body or antrum are epidemiologically
and biologically distinct from adenocarcinomas situated
at or near the EGJ. While the incidence of distal gastric
carcinomas is decreasing in industrialized countries,
they still constitute a major global health problem. A
signiﬁcant proportion of patients with distal oesopha-
geal or gastric carcinomas presents in an advanced
disease stage resulting in poor overall survival.
23,24 A
ﬁrst trial with anti-HER2 therapy in advanced gastric
adenocarcinoma showed clinical beneﬁt, and with other
ongoing trials in advanced gastric and oesophageal
adenocarcinomas, reliable HER2 status assessment in
both oesophageal and gastric adenocarcinomas is likely
to become increasingly important.
HER2 status is usually determined by immunohisto-
chemistry (IHC) and/or in situ hybridization (ISH).
With IHC the four-tiered scoring system described
originally for the Food and Drug Administration (FDA)-
approved HercepTest  (Dako, Glostrup, Denmark) is
used widely, irrespective of the IHC method employed.
Samples scored as 0 and 1+ are negative, 2+ as
equivocal and 3+ as positive. In the original algorithm
for breast cancer, only cases with 2+ score had to be
retested with ISH. However, American Society of
Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines
25 require in-house validation
of 1+ and 3+ samples with ISH before a certiﬁed
laboratory can conﬁne ISH retesting to 2+ samples.
Recently, a modiﬁcation of the HercepTest
TM scoring
system for gastric carcinomas was proposed.
3 The
original system required circular staining for a 2+/3+
score and staining of >10% tumour cells in breast
cancer. As non-circular basolateral IHC staining was
observed frequently in gastric carcinomas, as well as
strong (3+) staining of <10% tumour cells in biopsies,
these elements were added to the original HercepTest 
system.
Novel rabbit monoclonal HER2 antibodies have been
introduced recently claiming higher avidity and lower
background staining. The 4B5 antibody (Ventana
Medical Systems, Tucson, AZ, USA) is directed against
the extracellular domain of the HER2-receptor and is
FDA-approved. Another antibody is SP3 (Labvision;
Thermo Fisher Scientiﬁc, Fremont, CA, USA) directed
against the intracellular domain providing clearer
staining, but possibly lower sensitivity.
26 Both anti-
bodies claim an excellent correlation with ISH.
27,28
The PathVysion
  FDA-approved ﬂuorescence ISH
(FISH; Abbott, Abbott Park, IL, USA) is the classic in situ
hybridization test using probes for HER2 and chromo-
some 17 (Chr17) concomitantly on one slide, allowing
for the calculation of a HER2:Chr17 ratio. Dako
PharmDx  FISH used for HER2 testing in the ToGA
trial
2,3,20 uses a similar approach. FISH requires a
ﬂuorescencemicroscopeandassessmentinbiopsieswith
heterogeneous staining patterns can be extremely
laborious. ISH methods allowing traditional transmitted
light microscopy have been introduced recently. The
dual-probe silver in situ hybridization (SISH INFORM
 ;
Ventana) uses two separate slides for the HER2 and
Chr17probeswhichallowsforacomputedHER2:Chr17
ratio. Excellent FISH/SISH correlation is claimed.
29
No results have been published previously using SP3
and/or 4B5 IHC or SISH in gastric or oesophageal
adenocarcinomas. We conducted a single institution
study in 146 patients using the two antibodies with
SISH. In addition, all cases showing 1+ immunoscore
or higher were retested with Dako FISH. The objective
was to determine the predictive value of both antibod-
ies for and the incidence of HER2-ampliﬁcation.
Patients and methods
The study includes biopsy specimens from 178 consec-
utive patients with the diagnosis of adenocarcinoma of
the stomach or distal oesophagus (study period 1999–
2007). Sufﬁcient material for immunohistochemistry
(IHC) and in situ hybridization (ISH) studies was
available in 146 cases with formalin-ﬁxed, parafﬁn-
embedded primary tumour biopsies. The average num-
ber of biopsies per case was 5.8 [range 2–14, standard
deviation (SD) 2.4]. Location of the tumour was noted
(distal oesophagus, gastric cardia, body or antrum).
Oesophago-gastric region (EGR) was deﬁned as the
distal oesophagus, the EGJ or gastric cardia. Distal
stomach was deﬁned as gastric body or antrum. On the
newly cut slides stained with haematoxylin and eosin
(H&E), the tumour was typed as ‘intestinal’, ‘diffuse’,
‘mucinous’ or ‘mixed’ using the Laure ´n classiﬁcation.
HER2 IHC studies were carried out on the NeXes
stainer (Ventana) using 3-lm slides after antigen
retrieval (10 mm citrate, pH 7.3, boiling time 25 min).
On all slides, three breast cancer tumour samples with
an immunoscore of 0, 1+ and 3+ were used as controls.
The rabbit monoclonal antibody SP3 was used at a
dilution of 1:20 with a 32-min incubation time at 37 C.
Subsequently, iView DAB,3,3¢ – diaminobenzidine,
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practice, 300 cases of breast cancer specimens were
compared with this SP3 protocol in comparison with
DAKO FISH (see below for protocol), yielding excellent
concordance. Similarly, 4B5 was applied in prediluted
form as provided by the manufacturer.
For scoring of HER2 immunoreactivity, the modiﬁed
Herceptest  four-tiered scoring system developed for
gastric adenocarcinoma by Hofmann et al.
3 was used;
scores were: 0 (negative): no staining or membrane
staining in <10% of cells; 1+ (negative): faint/barely
perceptible membrane reactivity in >10% of cells; cells
are only stained in part of their membrane; 2+
(equivocal): weak to moderately complete or basolat-
eral reactivity in >10% of tumour cells; and 3+
(positive): moderate to strong complete or basolateral
reactivity of >10% of tumour cells. Cohesive IHC 3+
clones irrespective of the proportion of staining cells,
i.e. <10%, are also considered positive, as only biopsy
material was examined. The number of biopsies, the
number of positive biopsies and HER2-immunoreactiv-
ity expressed as a percentage of total tumour present
was noted. A histoscore (H-score) was calculated:
HER2 H-score = [percentage immunoreactive tumour
cells (0–100%)] · [immunoscore (0, 1, 2 or 3)].
Background staining was noted in 4B5 immunostain-
ing; ‘strong’ background was speciﬁed as both nuclear
and diffuse cytoplasmic staining, and ‘light’ back-
ground as diffuse cytoplasmic immunoreactivity only.
SISH was studied in all cases using the INFORM
HER2 DNA (Ventana) kit with HER2 and Chr17 probes
on separate serial-sectioned 4-lm slides with 8 min and
12 min pepsin pretreatment, respectively. SISH was
carried out using the Benchmark XT stainer (Ventana)
with an otherwise standardized protocol supplied by
the manufacturer.
FISH was carried out with the HER2 FISH Phar-
mDx  kit (Dako) in 40 cases with SP3 and/or 4B5
HER2-immunoreactivity of 1+ and higher; two cases
with only strong background staining in 4B5 immu-
nohistochemistry were added. Three-micrometer slides
were deparafﬁnized, placed in pretreatment solution at
95 C for 10 min, and after 15 min cooling at room
temperature (RT) put into wash buffer twice for 3 min.
Then, pepsine was applied for 6 min at RT and the
washing step was repeated. After dehydration in
graded ethanol slides were left to dry at RT for 6 min,
and after addition of 10 ll HER2/Chr17 probe mix a
coverslip with sealant was applied and slides were
placed in the ThermoBrite Hybridizer (StatSpin, Nor-
wood, MA, USA). Denaturation step was 5 min at 82 C
followed by overnight hybridization at 45 C. Slides
were then retrieved from the Hybridizer, coverslips
were removed and stringent washing at 65 C was
carried out followed by wash buffer treatment. Finally,
mounting medium was applied with a new coverslip.
Slides were stored at )20 C until assessment.
ISH assessment was performed on a Zeiss Axioscope
40 ﬂuorescence microscope with ·40/N.A.1.3 and
·100/N.A.1.3 (oil) objectives. SISH slides were counted
using the same objectives but with bright ﬁeld light.
Before ISH assessment the serialslidesstained with H&E,
SP3 and 4B5 antibodies were re-evaluated. In the ISH
slides, all tumour areas were assessed. Areas containing
the highest HER2 counts were assessed preferentially by
counting HER2 and Chr17 signals in at least 20 nuclei.
HER2:Chr17 ratios were calculated. When counts
exceeded 300 per 20 nuclei, >300 was noted, and a
HER2:Chr17 ratio of >6 was assumed. Positive ISH was
deﬁned as a HER2:Chr17 ratio of ‡2.2. Polysomy was
deﬁned as an average of ‡3 Chr17 signals per nucleus.
Of all slides with dual (SISH and FISH) assessments,
photomicrographs were taken and stored in Research
Assistant 5 (RVC, Baarn, the Netherlands).
Results
tumour characteristics
Histological characterics and the anatomical location
of the 146 gastro-oesophageal tumours are presented
in Table 1. Biopsies of 72 adenocarcinomas were from
the EGR,; 44 (61%) from the distal oesophagus and 28
(39%) from the gastric cardia. Sixty-three were classi-
ﬁed as intestinal type, six as mixed and three as
mucinous. Seventy-four adenocarcinomas were from
the distal stomach, 24 (32%) in the gastric body and
50 (68%) in the antrum. Fifty-four were of intestinal
type, nine mixed, nine diffuse and two of mucinous
type (Table 1).
her2 immunohistochemistry
SP3 immunoreactivity (Figure 1) was completely
absent in 125 (86%) cases. An immunoscore of 1+
was seen in four, 2+ in six and 3+ in 11 cases.
Membranous 4B5 immunoreactivity (Figure 2) was
absent in 106 (72%) cases; immunoscores of 1+ were
present in 17 cases, 2+ in six and 3+ in 17. All cases
with immunoscores of 1+ and higher showed immu-
noreactivity in at least 10% of tumour cells. U-shaped
basolateral staining was often noted. Background
staining was entirely absent with the SP3-antibody.
The 4B5 stains showed invariably extensive cytoplas-
mic background staining of the gastric foveolar layer
(Figure 5A); intestinal metaplasia when present also
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In addition, cytoplasmic background staining of
tumour was noted in 40 (27%) cases, of which seven
(5%) were strong with nuclear immunoreactivity. In
an additional two cases, only strong background
staining was noted without notable membranous
staining (Figure 5B) (Table 2).
her2 sish/fish versus immunoscore
SISH was performed in all 146 cases (Table 3a;
Figure 3). In some cases of SISH some nuclear haze
was present, possibly as a result of the ﬁxation time of
approximately 6 h (Figure 5C). All 17 cases with SP3
immunoscores 2+/3+ were ampliﬁed, as were ﬁve of
129 (4%) cases with negative SP3 immunohistochem-
istry (immunoscores 0/1+). Only one case of 123 with
4B5 immunoscores 0/1+ was ampliﬁed, and 21 of
23 (91%) cases with immunoscores 2+/3+. The two
ampliﬁed cases with SP3-immunoscore 0 were scored
2+ on 4B5 immunohistochemistry. The three ampli-
ﬁed cases with SP3-immunoscore 1+ were 2+ in the
4B5 in two cases and 1+ in one case. Two cases
with strong 4B5 background staining of nuclei
(but no membranous staining) were not ampliﬁed.
Sensitivity for ampliﬁcation was 77.3% for SP3 and
95.5% 4B5 IHC-positive cases as deﬁned by immuno-
scores2+/3+.Speciﬁcitywas100%forSP3-positiveIHC
and 98.4% for 4B5-positive IHC, respectively. The
positive predictive value (PPV) of SP3-positivity was
100% and the negative predictive value (NPV) 96.1%.
For 4B5 the PPV was 91.3% and the NPV 99.2%.
Of 42 FISH procedures performed (Figure 4) the
results were identical to SISH. Twenty-two cases were
ampliﬁed (Table 3b). Granular red background staining
was seen in a minority of cases in both tumour and
normal epithelial cells (Figure 5D).
heterogeneity of her2 positivity
Heterogeneity of HER2-immunoreactivity was the
dominant pattern, and areas of HER2 ampliﬁcation
closely matched positive HER2-immunoreactivity. The
percentage of tumour staining for an antibody without
regard to immunoscore, the number of positive biopsies
and/or calculated H-score did not predict ampliﬁcation
status. The only generalization that could be made was
that most ampliﬁed cases had a 2+/3+ immunoscore
with SP3, and 3+ (any percentage) or 2+ (>50%
tumour area) with 4B5 IHC (Table 4).
polysomy
Polysomy deﬁned as ‡3 Chr17 copies per cell was
present in 28 cases (19.2%). Polysomy was noted in
seven of 22 (32%) ampliﬁed cases showing invariably
‡5 HER2 signals per nucleus. In contrast, polysomy
present in 21 of 104 cases had <5 HER2 signals per
nucleus. Therefore, assessment of polysomy – often a
striking ﬁnding in tumours in our study – did not
contribute to the prediction of ampliﬁcation.
her2 amplification and anatomical location/
histological type
Of the total of 117 adenocarcinomas of intestinal type,
20 (17%) showed HER2-ampliﬁcation; 17 cases were
located in the EGR and two in the distal stomach. Two
of 15 cases (13%) with mixed-type histology were also
ampliﬁed and were located in the distal stomach. None
of the 14 cases with diffuse or mucinous types showed
ampliﬁcation (Table 5).
Of the tumours situated in the EGR, 17 (24%) were
HER2 ampliﬁed: 12 of 44 distal oesophageal adeno-
carcinomas and ﬁve of 28 cardia carcinomas. In the
Table 1. Histological
37 classiﬁcation and anatomical position of the adenocarcinomas
Laure ´n classiﬁcation
Anatomical position
Oesophagus Cardia Total EGR Body Antrum Total distal stomach
Intestinal 40 (91%) 23 (82%) 63 (88%) 15 (62%) 39 (78%) 54 (73%)
Mixed 3 (7%) 3 (11%) 6 (8%) 6 (25%) 3 (6%) 9 (12%)
Diffuse 1 (2%) 2 (7%) 3 (4%) 3 (13%) 6 (12%) 9 (12%)
Mucinous 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (4%) 2 (3%)
Total 44 (100%) 28 (100%) 72 (100%) 24 (100%) 50 (100%) 74 (100%)
EGR, Oesophago-gastric region.
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Figures 1 and 2. Figures 1 [SP3 immunohistochemistry (IHC)] and 2 (4B5 IHC) show identical cases. 1A, basolateral staining in SP3
(score 1+) but in 2A a 3+ staining pattern in 4B5; 1B, 2B, 1+ staining in both SP3 and 4B5; 1C, 2C (low magniﬁcation),
heterogeneous staining with 3+ pattern in the right half of the tumour and a 1+ staining in the left side, identical in SP3 and 4B5;
1D, 2D, detail of the 1+/3+ transition zone.
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two of 24 body and three of antral carcinomas.
Discussion
In a study of 146 cases with biopsies of primary
oesophagus and gastric adenocarcinomas, frequent
HER2-immunoreactivity using two novel rabbit mono-
clonal antibodies was identiﬁed. Both SP3 and 4B5
immunostaining had a high positive predictive value
for HER2-ampliﬁcation. 4B5 had a much higher
negative predictive value than SP3. SISH, when
compared with FISH in selected cases, yielded identical
results compared with FISH. HER2-ampliﬁcation was
most often present in biopsies of oesophagus and
gastric cardia adenocarcinomas (27% and 18%, respec-
tively); ampliﬁcation was less frequent in adenocarci-
nomas of the body and antral region (7%).
Many studies have been published on the concor-
dance of HER2 immunohistochemistry and in situ
hybridization in breast cancer,
25 focusing usually upon
the rabbit polyclonal antibody A408 (used in Hercep-
Test ) or the mouse monoclonal CB11 (used in the
previous generation of Ventana Pathway
 ; Ventana),
both FDA-approved kits. In daily practice the applica-
tion of these antibodies results in a relatively high
percentage of equivocal 2+ immunoscores. In order to
achieve an unequivocal 3+ immunoscore pattern in
cases with high ampliﬁcation a high background
in normal tissue has to be accepted, precluding easy
and reproducible assessment of immunohistochemis-
try. The new generation of more avid rabbit mono-
clonal antibodies has been developed in order to
produce better signal-to-background patterns. In the
ﬁeld of oestrogen receptor immunohistochemistry, the
new SP1-antibody has become an acclaimed test. SP3
and 4B5 are new rabbit monoclonal antibodies directed
against the intracellular and extracellular of the HER2-
receptor, respectively.
Ricardo et al.
28 reported a signiﬁcant level of agree-
ment between SP3 and CB11 IHC in breast carcinomas
Table 2. SP3 versus 4B5 human epidermal growth factor
receptor 2 (HER2) immunoscores
SP3
4B5
0 1+ 2+ 3+ Total
0 105 15 5 0 125 (86%)
1+ 1 2 1 0 4 (3%)
2+ 0 0 0 6 6 (4%)
3+ 0 0 0 11 11 (7%)
Total 106
(72%)
17
(12%)
6
(4%)
17
(12%)
146
(100%)
Table 3. Human epidermal growth factor receptor 2 (HER2) SP3 and 4B5 immunoscores versus (a) silver in situ hybridization
(SISH), (b) ﬂuorescence in situ hybridization (FISH)
SP3
ISH
4B5
ISH
Negative Positive Total Negative Positive Total
(a)
0 123 (98%) 2 (2%) 125 0 106 (100%) 0 (0%) 106
1+ 1 (25%) 3 (75%) 4 1+ 16 (94%) 1 (6%) 17
2+ 0 (0%) 6 (100%) 6 2+ 2 (33%) 4 (66%) 6
3+ 0 (0%) 11 (100%) 11 3+ 0 (0%) 17 (100%) 17
Total 124 22 146 Total 124 22 146
(b)
0 19 (90%) 2 (10%) 21 0 2 (100%) 0 (0%) 2
1+ 1 (25%) 3 (75%) 4 1+ 16 (94%) 1 (6%) 17
2+ 0 (0%) 6 (100%) 6 2+ 2 (33%) 4 (66%) 6
3+ 0 (0%) 11 (100%) 11 3+ 0 (0%) 17 (100%) 17
Total 20 22 42 Total 20 22 42
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Figures 3 and 4. Figures 3 [silver in situ hybridization (SISH) and 4 [ﬂuorescence in situ hybridization (FISH)] with identical cases. 3A, 4A, high
ampliﬁcation; 3B, 4B, low ampliﬁcation; 3C, 4C (lower magniﬁcation), area with (white arrow) and without (yellow arrow) magniﬁcation;
3D, chromosome 17 SISH: polysomy with >3 copies chromosome 17 per nucleus; 4D, polysomy. FISH: red dots, human epidermal growth factor
receptor 2 (HER2); green dots, chromosome 17.
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claimed easier assessment of SP3 immunostains. How-
ever, of 50 CISH-ampliﬁed samples 21 cases showed
negative SP3/CB11 IHC scores. Nunes et al.
31 reported
a better negative predictive value of SP3 immunohis-
tochemistry, with CB11 being slightly inferior, but the
Herceptest being equivalent to SP3. In a recent update
of UK recommendations on HER2 testing,
32 Walker
et al. reported equivalent results of 4B5 in comparison
with Herceptest, which is in concordance with a report
of the quality assurance programme Nordiqc.
33
In our study, both the SP3 and 4B5 yielded good
correlations with both in situ hybridization methods.
SP3 IHC produced clear immunostains facilitating
rapid and easy assessment. However, ﬁve of the 22
ampliﬁed cases were SP3-IHC negative, two (of 21)
cases with a complete negative staining pattern and
three (of four) cases with a 1+ pattern. The 4B5
antibody exhibited different staining characteristics:
only one (of 19) negative in IHC (1+ score) case was
ampliﬁed, as were 20 (of 22) cases with positive IHC
(score 2+/3+). The 4B5 was considerably more sensi-
tive than the SP3, with a better correlation with in situ
hybridization. However, some drawbacks of the 4B5
IHC were apparent: distinct cytoplasmic background
staining was present almost invariably in the foveolar
layer of the stomach; in addition, strong cytoplasmic
and even nuclear background could be seen in some
tumour areas. No ampliﬁcation was present in the
foveolar or tumour cells exhibiting background stain-
ing but assessment of IHC was occasionally hindered by
these phenomena, which are not seen in breast
pathology.
Due to its recent introduction, few studies com-
paring 4B5 with other antibodies have been
published in breast carcinomas. Powell et al.
33
AB
C D
Figure 5. A, 4B5 immunohistochemistry (IHC): background staining in foveolar layer of gastric epithelium; B, 4B5 IHC: strong nuclear and
cytoplasmic background staining in a diffuse type adenocarcinoma; C, human epidermal growth factor receptor 2 (HER2) silver in situ
hybridization (SISH): nuclear haze; D, ﬂuorescence in situ hybridization (FISH): red granular background staining of some nuclei (encircled)
among nuclei showing high ampliﬁcation.
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less background and better concordance with FISH
using 4B5 in 322 breast carcinomas in comparison
with CB11. Egervari et al.
34 compared six HER2
antibodies in a tissue microarray (TMA) composed of
199 breast cancers with FISH. In this array, ampli-
ﬁcation was present in 23 cases. In contrast to our
ﬁndings, they found that some cases with immuno-
scores of 0/1+ with 4B5 IHC showed ampliﬁcation.
This underscores the need for in-house validation
of immunohistochemistry prior to limiting in situ
hybridization to the category of 2+ immunoscores, as
required by 2007 ASCO/CAP HER2 guidelines for
breast cancer.
25
Reported frequencies of positive HER2-immunoreac-
tivity in gastro-oesophageal cancer vary extensively.
Table 6 lists the studies with full-paper reports in
which in situ hybridization has been carried out in
more than 50 cases. A comprehensive review by
Hofmann et al.
3 described 3264 cases of gastric
adenocarcinoma showing a positivity rate of 17.6%
deﬁned by IHC. In our selection of ISH-conﬁrmed HER2
status in Table 6, this percentage is lowered to 12%.
Even after detailed review of the full-paper reports, it
remains unclear whether adenocarcinomas of the
gastric cardia are included in the studies listed in
Table 6, let alone the relative contribution of these
tumours to overall ﬁndings. Thus, our ﬁnding of a 7%
Table 4. SP3 and 4B5 immunoscores versus percentage (IHC)-positive cells in ampliﬁed/non-ampliﬁed tumours
ISH negative
SP3
ISH positive
SP3
% positive cells in IHC
Subtotal
% positive cells in IHC
Subtotal 0 1–10 11–50 51–75 76–100 0 1–10 11–50 51–75 76–100
0 123 0 0 0 0 123 0 0 1 1 0 0 2
1 + 0 00011 1 + 0 02013
2 + 0 00000 2 + 0 02046
3 + 0 00000 3 + 0 04071 1
4B5 0 1–10 11–50 51–75 76–100 Subtotal 4B5 0 1–10 11–50 51–75 76–100 Subtotal
0 106 0 0 0 0 106 0 0 0 0 0 0 0
1+ 0 3 10 0 3 16 1+ 0 0 1 0 0 1
2 + 0 02002 2 + 0 12014
3 + 0 00000 3 + 0 060 1 11 7
ISH, In situ hybridization.
Table 5. Number (and percentage of biopsies) of human epidermal growth factor receptor 2 (HER2) ampliﬁed cases versus
Laure ´n classiﬁcation and anatomical location
Laure ´n
Anatomical position
Oesophagus Cardia Total EGR Body Antrum Total distal stomach
Intestinal 12 (30%) 5 (22%) 17 (27%) 1 (7%) 2 (5%) 3 (6%)
Mixed 0 (0%) 0 (0%) 0 (0%) 1 (17%) 1 (33%) 2 (22%)
Diffuse 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Mucinous 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Total 12 (27%) 5 (18%) 17 (24%) 2 (8%) 3 (6%) 5 (7%)
EGR, Oesophago-gastric region.
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stomach is no outlier; if cardia carcinomas are
included, an 11% positivity rate is reached in the
present study. Bang et al.
2 claimed a 22.1% HER2-
positivity in 3280 cases of advanced, recurrent and/or
metastatic gastric adenocarcinomas, as deﬁned by
either 3+ immunoscore using HercepTest  or ampli-
ﬁcation with Dako FISH in an abstracted ToGA trial
report. Adenocarcinoma of the stomach and the
gastro–oesophageal junction had a HER2-positivity of
20.9% and 33.2%, respectively. This is substantially
higher than most reports, including the present study.
In contrast to the present study, they found 4.9% FISH
positive cases in which IHC was completely negative,
and a 15% ampliﬁcation rate when the immunoscore
was 1+. Subsequent analysis failed to show a clinical
beneﬁt of trastuzumab in the FISH-positive but immu-
nonegative subgroups. Another possible explanation
might be that patients with advanced disease only were
accrued for the ToGA trial, while HER2 ampliﬁcation
could be seen to be a late event in oncogenesis. The
average HER2-positivity rates of the patients included
in the ToGA at the time of the report by Bang et al. did
not vary according to the geographical region (Europe
or Asia), but was a function of histological type in
concordance with our study.
The few larger studies with in situ hybridization-
conﬁrmed HER2 status in oesophageal adenocarci-
noma report a HER2-positivity rate of at least 15%. Our
27% HER2 ampliﬁcation rate is in line with substantial
higher HER2-positivity in oesophageal carcinoma
rather than (distal) gastric adenocarcinoma. Unfortu-
nately, questions concerning deﬁnitions, segmentation
of oncological entities, division of treatment groups
and different research interests hinder a comprehensive
view of HER2-positivity rates of the anatomical regions
comprising the distal oesophagus and the entire
stomach.
An important difference in HER2 immunoreactivity
and ampliﬁcation between breast cancer and gastro-
oesophageal adenocarcinomas is the striking heteroge-
neity of HER2-positivity in the latter. The 2007 ASCO/
CAP HER2 Guidelines
25 in breast cancer demands
HER2-immunoreactivity/ampliﬁcation in at least 30%
of breast cancer tumour areas in order to render a
HER2-positivity as a conclusion. Hofmann et al.
3 has
proposed allowing even less than the original Hercep-
Test  10% 3+ pattern of immunoreactivity in biopsies
of gastric carcinomas; in resection specimens the 10%
threshold is retained. The considerable heterogeneity of
HER2-positivity – 73% of all HER2-ampliﬁed cases in
our study – suggests that HER2 ampliﬁcation is a late
event in gastro-oesophageal adenocarcinomas. Never-
theless, a recent report of a large Phase III trial using
trastuzumab (ToGA trial
20) showed clinical beneﬁt,
especially in the group with both FISH positivity and an
immunoscore of at least 2+ using Herceptest. The
magnitude of clinical beneﬁt is similar to metastatic
breast carcinomas. This is remarkable, considering the
heterogeneous HER2-positivity in gastric adenocarci-
nomas in contrast to breast cancer, in which more
than 95% of HER2-positive cases are HER2-ampliﬁed
homogeneously. Recently, Marx et al.
1 reported highly
homogeneous HER2 ampliﬁcation in multiple sections
obtained from eight highly ampliﬁed cancers. It is
possible that this is a selection phenomenon, as they
studied 166 surgically resected gastric cancers cases,
27 of which showed unequivocal ampliﬁcation.
Silver in situ hybridization is a recently introduced
technique, being somewhat similar to CISH in that a
conventional microscope can be used to assess the
probe signals. Reports are still limited,
29,35 with fewer
Table 6. Human epidermal growth factor receptor 2 (HER2)
status in studies with in situ hybridization (ISH) on adeno-
carcinomas
Reference Method
n
(Total)
n
(Positive)
%
(Positive)
Stomach
Ishikawa
36 FISH 105 19 18%
Takehana
14 FISH 352 29 8%
Risio
18 FISH 72 11 15%
Varis
37 CISH 52 9 17%
Tanner
11 CISH 131 16 12%
Park
9 FISH/CISH 182 7 4%
Yano
38 FISH 200 54 27%
Kim
8 FISH 248 19 8%
Barros-Silva
19 FISH 463 38 8%
Marx
1 FISH 166 27 16%
Total 1.981 229 Mean 12%
Oesophagus
Brien
16 FISH 63 12 19%
Tanner
11 CISH 100 24 24%
Reichelt
4 FISH 110 16 15%
Total 273 52 Mean 19%
FISH, Fluorescence in situ hybridization; CISH, chromogenic
in situ hybridization.
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between FISH and SISH have been described. In our
study, 42 cases yielded identical results using both
techniques. Assessment of HER2/Chr17 signal in the
multiple biopsies was much faster and easier with SISH
in comparison with FISH, and allows a good correlation
between IHC and SISH using conventional techniques
such as ink-marking.
Most contemporary studies outside trials use the very
cost-effective TMA technique. However, given the high
incidence of heterogeneous HER2-immunoreactivity/
ampliﬁcation, we felt that using the TMA technique in
this ﬁeld could result in an underestimation of the
incidence of HER2-ampliﬁcation rates. While we did
not study resection specimens, the claim by Marx et al.
1
that HER2 ampliﬁcation is highly homogeneous is
contradicted by our ﬁndings in biopsy material.
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